Recognized as a touchENDOCRINOLOGY Future Leader 2026, Dr Leen Antonio discusses mentorship, research, and the role of clinician-scientists in advancing evidence-based endocrine care.

We are delighted to announce Dr Jonathan Mertens as a touchENDOCRINOLOGY Future Leader 2026, recognized for his emerging contributions to diabetes, metabolic health and translational endocrinology research. Dr Jonathan Mertens is an endocrinologist and researcher at Antwerp University Hospital and the ...

Dr Hironori Bando discusses the mentors who shaped his career, the rewards of supporting young researchers, and how research can deepen clinical insight and improve patient care.

Dr Georgia Colleluori discusses her journey into endocrinology, key career milestones in obesity and metabolism research, and the value of diverse experiences in shaping the next generation of researchers.

touchENDOCRINOLOGY Future Leaders 2026 is almost here! We are counting down to the launch of our annual celebration of the rising stars shaping the future of ENDOCRINOLOGY. Nominated by the global endocrinology community, these exceptional early-career clinicians and researchers have demonstrated outstanding promise through their contributions to clinical practice, research, education and leadership. Discover the inspiring individuals driving innovation and helping define the next generation of endocrinology care.

Topline data from the TRIUMPH-2 and TRIUMPH-3 trials show substantial weight loss, improved glycemic control, and favorable changes in cardiometabolic risk markers with the investigational triple hormone receptor agonist in adults with obesity and type 2 diabetes or established cardiovascular disease.

A new Endocrine Society statement has reinforced the importance of accurate diagnosis and appropriate clinical assessment before testosterone replacement therapy (TRT) is initiated in men with hypogonadism.1 Published July 16, 2026, the statement reiterates that treatment should not be based on symptoms alone and highlights continuing uncertainties around the long-term safety of TRT. It follows an FDA expert panel that reviewed testosterone eligibility criteria in December 2025, Society comments submitted to the FDA in February 2026, and new prescribing-pattern data presented at ENDO 2026, the Society's annual meeting, in June.

In a cross-sectional study of 6,996 patients with type 2 diabetes published in Endocrine, elevated serum uric acid was associated with higher odds of prevalent diabetic retinopathy (DR) among those diagnosed before 65 years of age, but not among those diagnosed at 65 years or older.1

Achieving clinically meaningful weight loss and cardiometabolic targets is a key goal in the management of obesity and type 2 diabetes, particularly in people at elevated cardiovascular risk. In this analysis of the phase 3 STEP UP T2D trial, researchers evaluated the extent to which participants treated with semaglutide 7.2 mg, semaglutide 2.4 mg or placebo achieved predefined BMI, waist-to-height ratio and cardiometabolic targets after 72 weeks. In this interview, Prof. Carel le Roux discusses the rationale for assessing these treatment targets, the key findings from the analysis and their implications for the use of higher-dose semaglutide in people with obesity and type 2 diabetes.